$Repare Therapeutics (RPTX.US)$ NEWS Repare Therapeutics & D...
NEWS
Repare Therapeutics & Debiopharm Announce First Patient Dosed in Phase 1/1b MYTHIC Trial Evaluating the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition
The collaboration between Repare Therapeutics and Debiopharm to evaluate the combination of lunresertib and Debio 0123 shows promise for cancer patients with high unmet medical needs.
The first patient dosed in the Phase 1/1b MYTHIC trial is a significant milestone, allowing for the swift execution of clinical development and further characterization of precision medicine therapies.
The first patient dosed in the Phase 1/1b MYTHIC trial is a significant milestone, allowing for the swift execution of clinical development and further characterization of precision medicine therapies.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
587Followers
66Following
3725Visitors
Follow